18 May 2014

Introducing The Rowboat
A advanced Covered Call system that is quite possibly The Holy Grail
of Investing.
Step 1: Sell the Put
( This is a Cash Covered Put, I have to have enough Cash to buy 100 shares per contract
if the option is exercised, this is also my maximum risk. )
BLUE @ $25.18
bluebird bio, Inc.
Sell To Open BLUE June14 $20.00 Put @ Market
Bid $1.60 / time $1.93
8% return in 32 days
$10,000 should generate $800.00
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on
developing gene therapies for severe genetic and orphan diseases. The
company s advanced product candidate is Lenti-D, which is in phase II/III
studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare,
hereditary neurological disorder affecting young boys; and LentiGlobin that is
in phase I/II studies for the treatment of beta-thalassemia major and severe
sickle cell disease in France, as well as a second phase I/II studies with
LentiGlobin for the treatment of beta-thalassemia major in the United States.
bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to
discover, develop, and commercialize disease-altering gene therapies in
oncology. The company was formerly known as Genetix Pharmaceuticals, Inc.,
and changed its name to bluebird bio, Inc. in September 2010. bluebird bio,
Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
bluebird bio, Inc.
150 Second Street

Cambridge, MA 02141

Phone: 339-499-9300

Website: http://www.bluebirdbio.com

Sign up with a auto-trading company and let your broker do the trades for you.

OHRP @ $8.88

Ohr Pharmaceutical, Inc.

Sell To Open OHRP June14 $5.00 Put @ Market

Bid .75c / Time .88c

15% return in 32 days

$10,000 should generate $1500.00

Sign up with a auto-trading company and let your broker do the trades for you.

OHR Pharmaceutical, Inc. operates as a biotechnology company. Its product line includes Squalamine, an anti-angiogenic small molecule with a novel intracellular mechanism of action that inhibits vascular endothelial, platelet derived, and basic fibroblast growth factors for the treatment of the wet form of age-related macular degeneration using an eye drop formulation. The company also offers OHR/AVR 118, a Phase IIa clinical trial product for the treatment of cancer cachexia. In addition, it owns various other compounds in earlier stages of development, including the PTP1b inhibitor trodusquemine and related analogs, which are in preclinical research stage. The company is headquartered in New York, New York.

Ohr Pharmaceutical, Inc. 489 5th Avenue

28th Floor

New York, NY 10017

Phone: 212-682-8452

Website: http://www.ohrpharmaceutical.net

News:

Remember, no more than 5 or 10% of your portfolio should ever be exposed in any one trade or position.

Example: if you have $30k total, each position can only be $3k exposure

Step 2 :IFit got Put to us, Now we”Lock-in” a profitandcomplete the rowboat

Sell the Covered Call

(Do not buy the stock just to sell the covered Call)

CYTK @ $4.69
Cytokinetics, Incorporated
Sell To Open CYTK August 2014 $5.00 Call @ Market
Currently .40c bid / .55c time
History:
Cost basis $5.00 per share.
Premiums collected: .25c per share
5%* Return in 1 months
05/16/2014 Buy CYTK – Stock Assignment $5.00
04/21/2014 Sell To Open CYTK May14 $5 Put $0.25
$10,000 would have generated $500.00

Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the treatment of heart failure. The company holds a license to develop and commercialize omecamtiv mecarbil and related compounds worldwide. It develops tirasemtiv, a fast skeletal muscle activator, as a potential treatment for diseases and medical conditions associated with neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the United States Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics, Incorporated has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure; and Astellas Pharma Inc. to develop a skeletal muscle activator structurally distinct from tirasemtiv, for non-neuromuscular indications. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.

Cytokinetics, Incorporated

280 East Grand Avenue

South San Francisco, CA 94080 Phone: 650-624-3000

Fax: 650-624-3010

Website:http://www.cytokinetics.com

PLUG @ $4.29

Plug Power Inc.

Sell To Open PLUG August 2014 $6.00 Call @ Market

Currently .35c bid / .38c time

History:

Cost basis $6.00 per share. Premiums collected: .40c per share 6.6% Return in 1 months

05/16/2014 Buy PLUG – Stock Assignment $6.00 04/21/2014 Sell To Open PLUG May14 $6 Put $0.40

$10,000 would have generated $660.00

Plug Power Inc., an alternative energy technology provider, is engaged in the design, development, manufacture, and commercialization of fuel cell systems for the industrial off-road markets worldwide. It is focused on proton exchange membrane (PEM) fuel cell and fuel processing technologies and fuel cell/battery hybrid technologies. The company s product line includes GenDrive, a hydrogen fueled PEM fuel cell system providing power to material handling vehicles; GenKey, its turn-key solution offering simplicity to customers transitioning their material handling vehicles to fuel cell power; GenFuel, its hydrogen fueling delivery system; and GenCare, its ongoing maintenance program for both the GenDrive fuel cells and GenFuel products. The company sells its products to businesses, government agencies, and commercial consumers through direct product sales force, original equipment manufacturers, and their dealer networks. Plug Power Inc. was founded in 1997 and is headquartered in Latham, New York

Plug Power Inc.

968 Albany Shaker Road Latham, NY 12110

Phone: 518-782-7700

Website: http://www.plugpower.com
Remember, no more than 5 or 10% of your portfolio should ever go into
any one trade or position. Example: if you have $30k total, each position can only
be $3k exposure

 

Remember, no more than 5 or 10% of your portfolio should ever go into
any one trade or position. Example: if you have $30k total, each position can only
be $3k exposure
How did we do last Month?
We got 2 more stocks to sell Covered Calls, see above
Current/Older Positions/History
This includes a running total for each open position.
Do not enter these positions.
CLSN @ $3.08
Celsion Corporation

HOLD : July 14 $3 Call still cooking

History:

Cost basis $2.00 per share. Premiums collected: $1.65 per share 82.5%* Return in 17 months

*

$10,000 would have generated $8250.00

actual trades:

04/21/2014 Sell To Open CLSN Jul14 $3 Call $0.40 03/24/2014 Sell To Open CLSN Apr14 4 Call $0.05

02/24/2014 Sell To Open CLSN Mar14 4 Call $0.05

01/21/2014 Sell To Open CLSN Feb14 $4 Call $0.25 12/23/2013 Sell To Open CLSN Jan14 $4 Call $0.15 11/18/2013 Sell To Open CLSN Dec13 $4 Call $0.25 02/19/2013 Sell To Open CLSN July 2013 $3 Call

(did not fill, because of Holiday) 0.00

02/15/2013 Buy CLSN – Option Assignment $2.00 01/22/2013 Sell To Open CLSN Feb13 $2 Put $0.30 12/24/2012 Sell To Open CLSN Jan13 $2 Put $0.20

Celsion Corporation, an oncology drug development company, engages in the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under Phase III clinical trial for primary liver cancer; under phase II clinical trial for colorectal liver metastasis; and under phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. for ThermoDox; a license agreement with Duke University to commercialize and use Duke’s thermo-liposome technology; and a joint research agreement with Royal Philips Electronics to evaluate the combination of Philips’ high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat various cancers. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

Celsion Corp.

997 Lenox Drive Suite 100

Lawrenceville, NJ 08648 Phone: 609-896-9100 Fax: 609-896-2200

materials or recommendations for educational purposes, this is not intended as Trading or Investment advice. We are not financial advisers. We cannot provide any advice as to whether or not options or our trading ideas are suitable investments for your particular financial situation. We are in the business of publishing our trade ideas for market analysis only. We highly recommend that our subscribers review their trading allocation with a qualified registered financial adviser/planner.

Legal Disclaimer: we do not exist to render and do not give legal, tax, economic or investment advice and disclaims all liability for the actions or inaction taken or not as a result of communications from or to its members, officers, directors, employees and contractors. Each individual should consult his/her own counsel, accountant and other advisors as to legal, tax, economic, investment and related matters concerning any type of investments.

This email and any files transmitted with it are solely intended for the use of the addressee(s) and may contain information that is confidential and privileged. If you receive this email in error, please advise us by return email immediately. Please also disregard the contents of the email, delete it and destroy any copies immediately.

In Loving Memory

Ronald E. Lee 1939-2013

News:

ONTY @ $2.69

HOLD No good options at this time

History:

Cost basis $5.00 per share. Premiums collected: 2.35 per share 47% Return in 29 months

$10,000 would have generated $4700.00

actual trades:

03/24/2014 Sell To Open ONTY May14 4 Call $0.15 03/18/2013 Sell To Open ONTY Jun13 5 Call $0.05 11/19/2012 Sell To Open ONTY Jan13 6 Call $0.55 05/21/2012 Sell To Open ONTY Nov12 7 Call $0.05 03/20/2012 Sell To Open ONTY May12 6 Call $0.05 03/16/2012 Buy ONTY – Option Assignment $5.00 03/16/2012 Buy To Close ONTY Mar12 $5 Put 02/21/2012 Sell To Open ONTY Mar12 $5 Put $0.70 01/30/2012 Sell To Open ONTY Feb12 5 Put $0.50 01/09/2012 Sell To Open ONTY Jan12 5 Put $0.30

Oncothyreon Inc.(ONTY), a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in Phase III clinical trials for the treatment of non-small cell lung cancer. The company also develops PX-866, a small molecule that is in Phase II trials. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine. The company operates in Canada, the United States, Barbados, and Europe. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Oncothyreon Inc

2601 Fourth Avenue Suite 500

Seattle, WA 98121 Phone: 206-801-2100 Fax: 206-801-2101

Website: http://www.oncothyreon.com

News:

PAAS @ $13.30

Hold

there are no good options at this time.

History:

Cost basis $36.00 per share.

Premiums collected: $3.50 per share

Dividends .63c

Total: $4.13

11.04% Return in 39 months

$10,000 would have generated $1104.00

actual trades:

12/11/2013 PAAS – PAAS QUALIFIED DIVIDEND .125 09/06/2013 PAAS – PAAS QUALIFIED DIVIDEND .125 06/19/2013 PAAS – PAAS QUALIFIED DIVIDEND .125 03/19/2013 PAAS – PAAS QUALIFIED DIVIDEND .125 12/04/2012 PAAS – PAAS QUALIFIED DIVIDEND .125 09/24/2012 Sell To Open PAAS Jan13 40 Call $0.05 01/30/2012Sell To Open PAAS Jul12 36 Call $0.20 12/06/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025

10/24/2011 Sell To Open PAAS Jan12 36 Call $0.40
10/22/2011 Buy To Close EXPIRED PAAS Oct11 36 Call
09/08/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025
06/20/2011 Sell To Open PAAS Oct11 36 Call $0.80
06/19/2011 Buy To Close EXPIRED PAAS JUN11 36 CALL
06/16/2011 PAAS QUALIFIED DIVIDEND $.025
05/23/2011 Sell To Open PAAS Jun11 36 Call $0.50
05/20/2011 Buy PAAS – Option Assignment $36.00
05/20/2011 Buy To Close PAAS May11 36 Put $0.00
04/18/2011 Sell To Open PAAS May11 36 Put $1.55

Pan American Silver Corp. engages in the exploration, development, extraction, processing, production, refining, reclamation, and operation of silver properties. The company also produces and sells gold, zinc, lead, and copper. As of April 27, 2011, it had seven silver mining operations in Mexico, Peru, Argentina, and Bolivia. The company was founded in 1979 and is headquartered in Vancouver, Canada.

Pan American Silver Corp.

625 Howe Street Suite 1500

Vancouver, BC V6C 2T6 Phone: 604-684-1175 Fax: 604-684-0147

Website: http://www.panamericansilver.com

News:

PAY @ $33.69

HOLD: PAY July 2014 $44.00 Call still cooking

Currently 30c bid / .38c time

History:

Cost basis $43.00 per share. Premiums collected: $3.61 per share 8.39% Return in 37 months

$10,000 would have generated $839.00

actual trades:

03/24/2014 Sell To Open PAY Jul14 44 Call $0.25

10/22/2012 Sell To Open PAY Jan13 44 Call $0.10

06/18/2012 Sell To Open PAY Oct12 $44 Call $0.35

05/21/2012 Sell To Open PAY Jun12 50 Call $1.00

04/16/2012 Sell To Open PAY May12 57.5 Call $1.02

04/16/2012 Buy To Close PAY Apr12 49 Call -$5.36

01/23/2012 Sell To Open PAY Apr12 49 Call $0.40

01/22/2012 Buy To Close EXPIRED PAY JAN12 49 CALL

10/31/2011 Sell To Open PAY Jan12 49 Call $0.90

10/31/2011 Buy To Close PAY Jan12 46 Call -$1.90

10/24/2011 Sell To Open PAY Jan12 46 Call $1.10

10/22/2011 Buy To Close EXPIRED PAY Oct11 42 Call

08/23/2011 Sell To Open PAY Oct11 42 Call $0.60

08/21/2011 Buy To Close EXPIRED PAY AUG11 46 Call

07/19/2011 Sell To Open PAY Aug11 46 Call $1.05

07/17/2011 Buy To Close EXPIRED PAY JUL11 44 Call

06/20/2011 Sell To Open PAY Jul11 44 Call $0.75

06/17/2011 Buy To Close PAY Jun11 43 Put $0.00

06/17/2011 Buy PAY – Option Assignment $43.00

05/23/2011 Sell To Open PAY Jun11 43 Put $1.70

VeriFone Systems, Inc. designs, markets, and services electronic payment solutions that enable secure electronic payments among consumers, merchants, and financial institutions worldwide. The company provides countertop electronic payment systems that accept magnetic, smart card, and contactless/radio frequency identification cards; and support credit, debit, check, electronic benefits transfer, and various pre-paid products, as well as offers wireless system solutions. The company also provides products for the point of sale applications, which include displays, user-friendly interfaces, electronic cash registers (ECR) interfaces, durable key pads, and signature capture functionality; and contactless/near field communication (NFC) payment solutions for consumer-activated transactions using contactless cards, tokens, or NFC enabled mobile phones. In addition, it offers various products for petroleum companies, such as integrated electronic payment systems that combine card processing, fuel dispensing, and ECR functions, as well as secure payment systems for integration with petroleum pump controllers and systems. Further, the company provides server-based transaction products; secure payment hardware and software integration modules; and VeriShield Protect, a solution that

encrypts and protects consumer card data. Additionally, it offers client services, including payment system consulting, deployment, on-site and telephone-based installation and training, help desk support, repairs, replacement of impaired system solutions, asset tracking, and reporting; and project management services. The company serves financial institutions, payment processors, petroleum companies, retailers, government organizations, and healthcare companies, as well as independent sales organizations. The company was formerly known as VeriFone Holdings, Inc. and changed its name to VeriFone Systems, Inc. in May 2010. The company is headquartered in San Jose, California.

VeriFone Systems, Inc

2099 Gateway Place Suite 600

San Jose, CA 95110

Phone: 408-232-7800 Fax: 408-232-7811

Website:http://www.verifone.com

News:

PRKR @ $5.06

Parkervision Inc.

Hold: PRKR July14 $5 Call still cooking

History:

Cost basis $5.00 per share. Premiums collected: $1.00 per share 20% Return in 7 months

$10,000 would have generated $2000.00

actual trades:

04/21/2014 Sell To Open PRKR Jul14 $5 Call $0.25 03/24/2014 Sell To Open PRKR Apr14 5.5 Call $0.15

12/23/2013 Sell To Open PRKR Mar14 $6 Call $0.15 11/15/2013 Buy PRKR – Stock Assignment $5.00

10/21/2013 Sell To Open PRKR Nov13 $5 Put $0.45

ParkerVision, Inc. designs, develops, and markets proprietary radio frequency (RF) technologies and products for use in semiconductor circuits for wireless communication products in the United States. It offers its technologies for processing RF waveforms in wireless applications. Its technology applies to both transmit and receive functions of a radio transceiver. The transmit portion of the technology, Direct2Power, enables the transformation of a baseband data signal to an RF carrier waveform at the desired power output level in a single unified operation. The receiver portion of the technology,

Direct2Data, enables the direct conversion of an RF carrier to a baseband data signal. The company also provides engineering consulting and design services to its customers to assist them in developing prototypes and/or products incorporating its technologies. It focuses on incorporating its technologies into mobile handsets for 3G and 4G cellular networks, as well as to other wireless products that are related to networks serving mobile handsets, such as tablets, data cards, femtocells, machine-to-machine, and embedded applications. The company s technology is also used in non-cellular radio applications comprising military radios and cable modems. ParkerVision, Inc. was founded in 1989 and is headquartered in Jacksonville, Florida.

QCOR @ $90.02

Questcor Pharmaceuticals, Inc.

HOLD : QCOR July 2014 $80 Call still cooking

History:

Cost basis $70.00 per share. Premiums collected: $6.10 per share 8.71% Return in 3 months

$10,000 would have generated $871.00

actual trades:

03/24/2014 Sell To Open QCOR Jul14 80 Call $3.10 03/21/2014 Buy QCOR – Stock Assignment $ 70.00 02/24/2014 Sell To Open QCOR Mar14 70 Put $3.00

Sign up with a auto-trading company and let your broker do the trades for you.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Acthar Gel, an injectable drug for the treatment of acute exacerbations of multiple sclerosis in adults; to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; and as monotherapy for the treatment of infantile spasms in infants and children under two years of age. The company s H.P. Acthar Gel also focuses on rheumatology-related conditions, including collagen diseases and rheumatic disorders. In addition, it offers Doral for the treatment of insomnia. The company sells its Acthar primarily to specialty pharmacies; and Doral to pharmaceutical wholesalers. Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Anaheim, California.

Questcor Pharmaceuticals, Inc.

1300 North Kellogg Drive Suite D

Anaheim, CA 92807

Phone: 714-786-4200 Fax: 714-789-4229

Website: http://www.questcor.com

SCTY @ $50.19

solar city corporation

HOLD:SCTY July 14 $80 Call still cooking

History:

Cost basis $75.00 per share. Premiums collected: $8.93 per share

11.19% Return in 3 months

$10,000 would have generated $1062.00

actual trades:

04/21/2014 Sell To Open SCTY Jul14 $80 Call $1.31 03/24/2014 Sell To Open SCTY Apr14 80 Call $0.55 03/21/2014 Buy SCTY – Option Assignment $75.00 02/24/2014 Sell To Open SCTY Mar14 75 Put $7.07

SolarCity Corporation engages in the design, installation, and sale or lease of solar energy systems to residential and commercial customers, and government entities in the United States. It provides solar energy systems; and energy efficiency products and services, including home energy evaluation, and energy efficiency upgrade products and services. The company also sells electricity generated by solar energy systems to customers. In addition, it markets and installs electric vehicle charging equipment to residential and commercial customers through retail partnerships. The company was founded in 2006 and is headquartered in San Mateo, California.

SolarCity Corporation

3055 Clearview Way

San Mateo, CA 94402

Phone: 650-638-1028 Fax: 650-638-1029

Website:http://www.solarcity.com

TRGT @ $3.73

HOLD: TRGT Aug14 10 Call still cooking

History:

Cost basis $12.50 per share.

Premiums collected: $2.65 per share 21.% Return in 31 months

$10,000 would have generated $21200.00

actual trades:

04/21/2014 Sell To Open TRGT Aug14 $10 Call $0.40 02/21/2012 Sell To Open TRGT May12 15 Call $0.25 11/28/2011 Sell To Open TRGT Feb12 15 Call $0.40 11/18/2011 Buy To Close TRGT Nov11 12.5 Put 11/18/2011 Buy TRGT – Option Assignment $12.50 10/23/2011 Sell to Open TRGT Nov 11 $12.50 PUT $1.60

Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the nervous system. Its lead program, TC-5214, a nicotinic channel modulator, is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder (MDD) and in Phase 2b clinical trial for switch monotherapy in patients with MDD. The company s novel small molecule product candidates under Phase 2 clinical development include TC-5619 for treating negative symptoms and cognitive dysfunction in schizophrenia, attention deficit/hyperactivity disorder, and Alzheimer s disease; AZD3480 as a treatment for mild to moderate Alzheimer s disease; AZD1446 as a treatment for Alzheimer s disease; and TC-6987 for the treatment of inflammatory disorders, including asthma and Type 2 diabetes. It has a collaborative research and license agreement with AstraZeneca AB for the development and commercialization of AZD3480, TC-5214, and TC-5619; and a product development and commercialization agreement with SmithKline Beecham Corporation to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. The company was founded in 1997 and is based in Winston-Salem, North Carolina.

Targacept, Inc.

200 East First Street Suite 300

Winston-Salem, NC 27101-4165 Phone: 336-480-2100

Fax: 336-480-2107

Website: http://www.targacept.com

News:

Earnings report in February

VJET @ $13.60

Voxeljet AG (VJET)

HOLD : No good options at this time

History:

Cost basis $55.00 per share. Premiums collected: $4.70 per share 8.5% Return in 6 months

$10,000 would have generated $850.00

actual trades:

02/24/2014 Sell To Open VJET May14 $60 Call 0.35c 12/23/2013 Sell To Open VJET Feb14 $60 Call 0.35c 11/18/2013 Sell To Open VJET Dec13 $55 Put $4.00

voxeljet AG provides three-dimensional (3D) printers and on- demand parts services. Its 3D printers employ a powder binding additive manufacturing technology to produce parts using various material sets. The company operates in two segments, Systems and Services. The Systems segment focuses on the production, development, and sale of 3D printers. It also offers consumables, such as particulate materials and proprietary chemical binding agents, maintenance contracts, and spare parts. The Services segment prints on-demand parts at its service center through its 3D printers, material sets, and in-house finishing capabilities. The company provides its 3D printers and on-demand parts services to industrial and commercial customers in automotive, aerospace, film and entertainment, art and architecture, engineering, and consumer product end markets in Europe, the Middle East, Africa, the Asia Pacific, and the Americas. voxeljet AG was founded in 1999 and is headquartered in Friedberg, Germany

Voxeljet AG

Paul-Lenz Strasse 1b

Friedberg, 86316

Germany

Phone: 49 821 7483 100

Fax: 49 821 7483 111

Website: http://www.voxeljet.de

News:

ZIOP @ $3.21

ZIOPHARM Oncology, Inc.

HOLD: ZIOP July14 $4 Call still cooking

History:

Cost basis $3.00 per share. Premiums collected: $.60 per share 20% Return in 13 months

$10,000 would have generated $833.00

actual trades:

01/21/2014 Sell To Open ZIOP Apr14 $6 Call $0.35 04/22/2013 Sell To Open ZIOP Jan14 $5 Call $0.05 04/19/2013 Buy ZIOP – Stock Assignment $3.00 03/18/2013 Sell To Open ZIOP Apr13 $3 Put $0.20

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO -201), a potent bi-functional DNA alkylating agent, is under Phase III trial for the treatment of first -line metastatic soft tissue sarcoma, as well as in a pivotal Phase III trial for first-line metastatic small cell lung cancer. The company s portfolio of clinical-stage product candidates also include IL-12 DNA, which is being tested in a Phase 2 study using synthetic biology to enable controlled, local delivery of therapeutic interleukin-12; Indibulin (ZIO-301), a novel, tubulin binding agent under Phase I/II trial in metastatic breast cancer; and Darinaparsin (ZIO- 101), a novel mitochondrial- and hedgehog-targeted agent. In addition, its portfolio comprises various research-stage candidates. The company s DNA therapeutics are being developed in partnership with Intrexon Corporation through a synthetic biology platform that allows for targeted, controlled production of therapies in humans with a biologic on/off switch. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York with operations center located in Boston, Massachusetts.

ZIOPHARM Oncology, Inc.

1180 Avenue of the Americas 20th Floor

New York, NY 10036

Phone: 646-214-0700 Fax: 646-214-0711

Website: http://www.ziopharm.com

News:

ZNGA @ $3.35

Hold

Take no action

There is no good option interest at this time.

History:

Cost basis $14.00 per share. Premiums collected: $2.05 per share 14.64% Return in 27 months

$10,000 would have generated $1464.00

actual trades:

03/19/2012 Sell To Open ZNGA Apr 2012 $16 Call $0.20 03/18/2012 Buy To Close EXPIRED ZNGA MAR12 $15 CALL 02/21/2012 Sell To Open ZNGA Mar12 15 Call $0.40 02/17/2012 Buy ZNGA – Option Assignment $14.00 02/17/2012 Buy To Close ZNGA Feb12 $14 Put

02/06/2012 Sell To Open ZNGA Feb12 14 Put $1.55

Zynga Inc. develops, markets, and operates online social games as live services on the Internet, social networking sites, and mobile platforms. The company offers its online social games under the CityVille, Zynga Poker, FarmVille, CastleVille, FrontierVille, Mafia Wars, Word with Friends, Hidden Chronicles, Zynga Bingo, Scramble With Friends, Slingo, and Dream Heights names. Its games are available on various platforms, including Facebook and other social networks, as well as mobile platforms, such as Apple iOS and Google Android worldwide. The company was formerly known as Zynga Game Network Inc. and changed its name to Zynga Inc. in November 2010. Zynga Inc. was founded in 2007 and is headquartered in San Francisco, California.

Zynga, Inc.

699 Eighth Street

San Francisco, CA 94103 Phone: 855-449-9642 Fax: 302-636-5454

Website: http://www.zynga.com

News:

Quote of the Month:

“As Buffet said in the speech, “He’s not looking at quarterly earnings projections, he’s not looking at next year’s earnings, he’s not thinking about what day of the week it is, he doesn’t care what investment research from any place says, he’s not interested in price momentum, volume or anything. He’s simply asking: What is the business worth?’”

Until Next Time

Brad Lee

The Options Oracle

https://theoptionsoracle.com/

The place for safer Investments

Established 23 February 2009
Ask The Oracle
Webinar Sunday 8 pmESTto explain
this newsletter, or other questions you might have.
Here is the link
https://secure.join.me/BradLeeOptions
There is no preregistration.
Please use the phone option for audio
Summary of Trades:
Cash Covered Puts
Sell To Open BLUE June14 $20.00 Put @ Market
Sell To Open OHRP June14 $5.00 Put @ Market
Stock Covered Calls
(do not buy into these positions)
Sell To Open CYTK Aug 2014 $5.00 Call @ Market
Sell To Open PLUG Aug 2014 $6.00 Call @ Market
Called away:
Nothing called away
Company News
New toll free number:
1-866-466-4617
I am slowing down on the videos and will
be increasing my Facebook posts.

Please “Like” us on Facebook.

https://www.facebook.com/OptionsOracle

Got a question or concern? Want to learn my philosophy and why it pays so well and consistently? Go to “contact us” https://theoptionsoracle.com/contacting-us/ and schedule a consultation.

Feel free to contact me personally!

Military discounts are here!

Thank you for your service!

Refer a Friend

The greatest compliment you can give me is to share me with your friends.

Company News
Auto Trading is now active!
Don’t want to be bothered doing the trades?
Auto-trading is for you. Your account will
automatically do whatever I do.
You are still in control, you set the limits either a
dollar amount or a percentage.
Go to the main site, the Auto-trade link is on the site
https://theoptionsoracle.com/auto-trading/
We will be doing a webinar Sunday 8 pm
est to explain this newsletter.
Here is the link
https://secure.join.me/BradLeeOptions
Disclosure: These are my actual trades.
Your subscription fee may be 100% TAX
DEDUCTIBLE if used for educational
business/investment purposes. Check with your
Licensed Professional adviser

Disclosure: These are my actual trades.

I am not telling you what to do, I am showing you what I am doing.

Your subscription fee may be 100% TAX DEDUCTIBLE if used for educational business/investment purposes. Check with yourLicensed Professional adviser

Options involve risk and are not suitable for all investors.
Prior to trading options, you must be approved for
options trading and read the Characteristics and
Risks of Standardized Options.
Copies of this document may also be obtained from your
broker, from any exchange on which options are traded,
by placing an order online, or by contacting the Options
Clearing Corporation directly at 1 N. Wacker Dr., Suite
500, Chicago, IL 60606. (1-888-678-4667).
Brad Lee AKA “The Options Oracle” and “The
Money Medic” is an individual investor who does
not manage money for any financial institution. You
are purchasing the list of stocks that he uses to
select options contracts he feels will return him the
highest, safest profits. Brad is not a broker, or
financial adviser. He is a remarkable investor who
has developed a successful strategy for himself,
and is willing to share some of his magic with you.
We urge you to paper trade these picks and learn
how to develop a strategy that is appropriate for
you. Thank You.
We make no recommendations on investment and
we do not provide financial, tax or legal advice.
Content and tools are provided for educational and
informational purposes only.
Disclaimer
Trading or investment in stocks, futures & options, and
commodity are subject to potential market risks. You can use our

Website: http://www.celsion.com